The ChiNext Index dropped more than 3% on Tuesday as steep declines in innovative drug development and computing hardware supply chain stocks weighed heavily on market sentiment. 永泰生物-B (IMMUNOTECH-B) was among the notable movers, though broader selling pressure dominated the session across both sectors.

Trading data showed that the pharmaceutical innovation segment faced significant profit-taking after a recent rally, with several high-flying names giving back gains. Meanwhile, the computing hardware chain, including semiconductor and server-related companies, also saw sharp corrections as investors rotated out of high-valuation technology positions.

Market analysts pointed to a combination of factors driving the selloff, including lingering concerns over sector valuations and profit-taking after recent outperformance. Despite the day's losses, some stocks exhibiting a bullish MACD golden cross signal have continued to show upward momentum, suggesting selective opportunities remain for traders.

The broader market indices mirrored the weakness, with the ChiNext Index leading declines amid a broad-based retreat. Investors are now closely watching for any policy cues or earnings updates that could stabilize sentiment in the coming sessions.